-The Telegraph New Delhi: Foreign corporations have created over 247,000 jobs through research and development (R&D) investments in India over the past decade, but most of the activities appear relatively unimportant with little long-term gains , researchers have said. The study, described as the first comprehensive assessment of foreign direct investment (FDI) in R&D, has challenged suggestions by Indian science policy makers and foreign corporations a decade ago that turning India into...

-The Hindu     Questioning a technology, especially of the kind that has serious unknowns and lacks clear social benefits, is not an attack on science Jairam Ramesh, former Environment Minister for India, made the brave decision in 2010 to tell his then apex regulator of genetically modified organisms (GEAC) that it had failed to properly use available science to determine the safety - to human health and the environment - of Bt brinjal,...

-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...

-The Economic Times CHENNAI: India's patent appeals board has denied Monsanto a patent for a genetically-engineered method of increasing climate resilience in plants. The decision is significant not only for Monsanto's loss of possible exclusivity in an increasingly important segment but also for the interpretation of India's home-grown clauses in patent law - these are unpopular with global companies - for the first time in the case of plants. The Intellectual Property...

-PTI India however maintained that the India Patent Act was in accordance with the TRIPS Agreement & the Paris Convention The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied. "PhRMA remains concerned about the deteriorating intellectual property environment in India," Mark Grayson, PhRMA spokesman told PTI. The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's...